LifeMD (NASDAQ:LFMD) Upgraded at B. Riley

B. Riley upgraded shares of LifeMD (NASDAQ:LFMD - Free Report) to a strong-buy rating in a research note published on Tuesday,Zacks.com reports. B. Riley also issued estimates for LifeMD's Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.10) EPS.

A number of other equities research analysts also recently weighed in on LFMD. Lake Street Capital started coverage on LifeMD in a research report on Tuesday, December 10th. They set a "buy" rating and a $12.00 price target on the stock. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. KeyCorp cut their price objective on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Finally, HC Wainwright increased their target price on shares of LifeMD from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $11.43.

Remove Ads

LifeMD Stock Down 3.9 %

Shares of NASDAQ:LFMD traded down $0.23 during midday trading on Tuesday, reaching $5.71. 1,491,039 shares of the company traded hands, compared to its average volume of 798,585. The firm's fifty day moving average price is $5.68 and its two-hundred day moving average price is $5.39. The firm has a market capitalization of $254.57 million, a price-to-earnings ratio of -8.92 and a beta of 1.50. LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $64.26 million during the quarter, compared to the consensus estimate of $57.43 million. Analysts forecast that LifeMD will post -0.56 earnings per share for the current year.

Insider Activity

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the transaction, the chief executive officer now directly owns 2,653,715 shares of the company's stock, valued at approximately $20,035,548.25. The trade was a 1.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 15.97% of the company's stock.

Institutional Investors Weigh In On LifeMD

A number of large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in LifeMD by 496.4% in the third quarter. JPMorgan Chase & Co. now owns 88,173 shares of the company's stock worth $462,000 after purchasing an additional 73,389 shares during the period. State Street Corp boosted its holdings in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after buying an additional 192,861 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of LifeMD by 852.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company's stock worth $637,000 after buying an additional 108,822 shares during the period. Geode Capital Management LLC increased its stake in shares of LifeMD by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company's stock worth $4,293,000 after acquiring an additional 83,598 shares in the last quarter. Finally, Mirador Capital Partners LP lifted its position in LifeMD by 139.3% during the 4th quarter. Mirador Capital Partners LP now owns 106,059 shares of the company's stock valued at $525,000 after acquiring an additional 61,731 shares during the period. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.